Real-world adverse event profile and signal characteristics of bevacizumab in glioma: a FAERS-based disproportionality analysis

This study delineates the adverse event spectrum of bevacizumab in patients with glioma, confirming prominent vascular and renal toxicities and revealing sex- and age-related differences in safety profiles. The findings highlight the need for heightened surveillance of vascular and renal events following bevacizumab exposure and provide hypothesis-generating evidence to inform future prospective studies.